These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Ratanatharathorn V, Karanes C, Lum LG, Uberti J, Dan ME, de Planque MM, Schultz KR, Cronin S, Leisz MC, Mohamed A. Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949 [Abstract] [Full Text] [Related]
3. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report. Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S. Natl Med J India; 2004 Jan; 17(2):71-3. PubMed ID: 15141598 [Abstract] [Full Text] [Related]
4. [Chronic granulocytic leukaemia (CGL): results of continuous busulphan mono-chemotherapy in 160 cases (1960-1980) (author's transl)]. Sánchez Fayos J, Outeiriño J, de Villalobos E, Valera M, Alonso M, Calabuig MT, Paniagua G. Sangre (Barc); 1981 Jan; 26(1):65-71. PubMed ID: 6942520 [No Abstract] [Full Text] [Related]
5. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Galimberti M, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Giardini C, Gaziev D, Erer B, Ripalti M, Rapa S. Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089 [Abstract] [Full Text] [Related]
6. Management of busulphan non-responsive chronic myeloid leukaemia. Roul RK, Singh AD. J Indian Med Assoc; 1982 Aug 01; 79(3):27-9. PubMed ID: 6960081 [No Abstract] [Full Text] [Related]
7. Pregnancy in a patient receiving busulphan for chronic myeloid leukaemia. Norhaya MR, Cheong SK, Hamidah NH, Ainoon O. Singapore Med J; 1994 Feb 01; 35(1):102-3. PubMed ID: 8009265 [Abstract] [Full Text] [Related]
8. [Varying course of pancytopenia after busulfan treatment of chronic myelocytic leukemia (CML)]. Krug K, Stenzel L. Folia Haematol Int Mag Klin Morphol Blutforsch; 1978 Feb 01; 105(2):181-7. PubMed ID: 79522 [Abstract] [Full Text] [Related]
9. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Bone Marrow Transplant; 2000 Oct 01; 26(7):711-6. PubMed ID: 11042650 [Abstract] [Full Text] [Related]
10. [Splenectomy for chronic myeloid leukaemia in the early and late phases (author's transl)]. Stolzenbach G, Garbrecht M, Delling G. Dtsch Med Wochenschr; 1977 Jun 17; 102(24):889-93. PubMed ID: 266988 [Abstract] [Full Text] [Related]
11. [High-dose busulfan with subsequent bone marrow transplantation in poor-risk forms of leukemia]. Urban C, Slavc I, Kaulfersch W, Teubl I. Wien Klin Wochenschr; 1987 Mar 06; 99(5):144-9. PubMed ID: 3554777 [Abstract] [Full Text] [Related]
12. [Indirubin in the treatment of chronic myelocytic leukemia (CML)--estimation of labelling index of bone marrow cells by 3H-TdR]. You YC, Mi JX, Wan JH, Yang TY, Wang ZC, Qian LS. Zhonghua Zhong Liu Za Zhi; 1987 Nov 06; 9(6):418-20. PubMed ID: 3482992 [Abstract] [Full Text] [Related]
13. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Cony-Makhoul P, Marit G, Boiron JM, Puntous M, Reiffers J. Bone Marrow Transplant; 1995 Jul 06; 16(1):69-70. PubMed ID: 7581131 [Abstract] [Full Text] [Related]
14. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience. Hassan HT, Krog C, Stockschläder M, Schleimer B, Zeller W, Krüger W, Erttmann R, Zander AR. Anticancer Res; 1997 Jul 06; 17(1B):589-99. PubMed ID: 9066585 [Abstract] [Full Text] [Related]
15. [Course and prognosis of chronic myeloid leukemia treated with busulfan. Study of 300 cases]. Ionescu V. Dtsch Med Wochenschr; 1971 May 14; 96(20):867-70. PubMed ID: 5280862 [No Abstract] [Full Text] [Related]
16. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B, Fasanaro A, Mele G. Br J Haematol; 2005 Jan 14; 128(2):234-41. PubMed ID: 15638859 [Abstract] [Full Text] [Related]
17. [Adrenal function in chronic myeloid leukemia]. Podolak-Dawidziak M, Silber-Kasprzak D. Acta Haematol Pol; 2005 Jan 14; 7(4):303-9. PubMed ID: 1069455 [Abstract] [Full Text] [Related]
18. Treatment of 100 cases of chronic myeloid leukemia with Myleran. Pawelski S, Topolska P, Rechowicz K, Krzyzanowska-Wozniakowska. Pol Med Sci Hist Bull; 1968 Jul 14; 11(3):101-4. PubMed ID: 5243952 [No Abstract] [Full Text] [Related]
19. Some biological and epidemiological characteristics of human leukaemia in Africans. Williams CK. IARC Sci Publ; 1984 Jul 14; (63):687-712. PubMed ID: 6598802 [Abstract] [Full Text] [Related]
20. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW. Cancer Treat Rep; 1984 May 14; 68(5):711-7. PubMed ID: 6373004 [Abstract] [Full Text] [Related] Page: [Next] [New Search]